Scribe Therapeutics has initiated a Phase 1 clinical trial of STX-1150, an epigenetic therapy that silences PCSK9 expression in the liver to reduce LDL cholesterol without modifying DNA sequence. Preclinical data demonstrated sustained LDL reductions exceeding 50 percent for approximately 18 months following a single dose, positioning epigenetic regulation as a distinct mechanism from genetic modification for cholesterol management.
Key Points
- Single-dose epigenetic silencing achieves 50%+ LDL reduction sustained 18 months
- Liver-targeted PCSK9 suppression without permanent DNA alterations
- Phase 1 trial enrolling 64 participants across Australia and New Zealand
Longevity Analysis
Chronic elevation of LDL cholesterol accelerates vascular aging and constrains circulation-dependent health across multiple systems. By targeting epigenetic regulation of PCSK9 rather than genetic modification, this approach offers sustained metabolic intervention without the permanence of gene editing, allowing reversibility if needed. The extended duration of effect from a single administration addresses a core challenge in longevity medicine: maintaining therapeutic benefit while minimizing ongoing intervention burden, reducing both pharmaceutical load and the metabolic cost of repeated dosing on detoxification capacity.
Original published by Longevity.Technology.